有3.5年的临床经验,用于治疗耐火性的perampanel
T Bin Teni1, N A Almutairi, S Abuhaimed
1Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
European review for medical and pharmacological sciences
|March 18, 2024
概括
佩拉曼奈尔在治疗耐药性方面表现出显著的疗效,超过66%的患者有反应. 虽然一般耐受性很好,但攻击性行为是导致停药的最常见副作用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 耐火性在患者管理中构成了重大挑战.
- 佩拉曼奈尔为难以控制的发作提供了潜在的辅助治疗选择.
研究的目的:
- 为了评估沙特阿拉伯耐火性患者的佩拉曼尼尔的实际有效性和耐受性.
- 评估与长期使用帕拉曼尼尔相关的不良事件.
主要方法:
- 从75名患者的医疗记录的回顾性分析治疗perampanel (2017年3月至2020年9月).
- 利用利物浦不良事件概况 (LAEP) 尺度来监测副作用.
- 评估了发作频率的减少和无发作率.
主要成果:
- 观察到的应答率为66.7%,其中22.7%的患者至少六个月没有发作.
- 13.3%的患者因不良反应,主要是攻击性行为和镇静而停止服用帕拉曼尼尔.
- 精神病并发症与增加的精神病和行为副作用有关 (p = 0.0206).
结论:
- 佩拉曼奈尔是一种有效的辅助治疗难治性发作,达到66.7%的响应率.
- 长期耐受性通常很好,但对行为副作用的监测至关重要.
- 患有精神病史的患者需要仔细监测诸如攻击性等不良事件.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
342
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
342
Antiepileptic Drugs: Potassium Channel Activators
181
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
181
Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39
Antiepileptic Drugs: GABAergic Pathway Potentiators
396
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
396
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
292
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
292
Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188


